PA
ARQT icon

PharVision Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

PharVision Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,999
Closed -$245K – 696
2025
Q3 		$245K Buy
+12,999
New +$205K 0.14% 346

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's ARQT Position: Q4 2025 in Review

PharVision Advisers sold out of Arcutis Biotherapeutics (ARQT) in Q4 2025, closing a stake of 12,999 shares — an estimated $245K sold.

PharVision Advisers first reported a position in ARQT in Q3 2025 and held it in 1 quarter. The position peaked at $245K in Q3 2025. 282 funds tracked by Wall St. Rank hold ARQT as of Q4 2025.

  • PharVision Advisers reported no remaining Arcutis Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 12,999 Arcutis Biotherapeutics shares in Q4 2025, an estimated $245K.
  • PharVision Advisers first reported a position in Arcutis Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Arcutis Biotherapeutics position peaked at $245K in Q3 2025.
  • 282 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.